Tarsus Pharmaceuticals Inc (TARS) financials
Tarsus Pharmaceuticals revenue and earnings by year
Tarsus Pharmaceuticals's revenue was $451 million in the fiscal year to December 31, 2025, up 146.7% from the year before. Net income was -$66.4 million, -14.7% of revenue. Since the fiscal year to December 31, 2021, revenue has grown 67.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 451 | 183 | 17 | 26 | 57 |
| Revenue growth | 146.7% | 948.6% | -32.4% | -54.7% | — |
| Gross profit | 421 | 170 | 16 | 25 | 55 |
| Gross margin | 93.2% | 93.0% | 90.9% | 96.3% | 96.4% |
| Operating income | -71 | -121 | -143 | -63 | -12 |
| Operating margin | -15.7% | -65.9% | -820.5% | -242.9% | -21.3% |
| Net income | -66 | -116 | -136 | -62 | -14 |
| Net margin | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% |
| Diluted EPS | -$1.59 | -$3.07 | -$4.62 | -$2.52 | -$0.67 |
| Free cash flow | -22 | -90 | -123 | -50 | 3 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TARS in Markets.
See also: TARS returns
No forecast, no recommendation. This page describes Tarsus Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.